XXI. Wilsede Meeting 2016

MODERN TRENDS IN HUMAN LEUKEMIA & CANCER
June 18 - 21, 2016  -  Wilsede, Germany

XXI. Wilsede Meeting 2016

MODERN TRENDS IN HUMAN LEUKEMIA & CANCER
June 18 - 21, 2016  -  Wilsede, Germany

XXI. Wilsede Meeting 2016

MODERN TRENDS IN HUMAN LEUKEMIA & CANCER

June 18 - 21, 2016  -  Wilsede, Germany

XXI. Wilsede Meeting 2016

MODERN TRENDS IN HUMAN LEUKEMIA & CANCER

June 18 - 21, 2016  -  Wilsede, Germany

 

08:00-14:00 Registration at University Medical Center (UKE) Hamburg-Eppendorf, Campus Lehre, N55/ Wilsede
16:30-16:40 Welcome Address
Boris Fehse & Nicolaus Kröger, Hamburg/DE
   
16:40-18:00 Session I: Stem cells & stroma
Chairs: Tsvee Lapidot, Rehovot/IL; Simon Mendez-Ferrer, Cambridge/UK
  16:40-17:05
Remodelling of Mesenchymal stroma cells by Acute Myeloid Leukemia (AML) Cells
  • Dominique Bonnet, London/UK
  17:05-17:30
Microenvironmental HSC regulation in space and time
  • Simon Mendez-Ferrer, Cambridge/UK
  17:30-17:55
Molecular and Functional Heterogeneity of Dormant HSCs
  • Nina Cabezas-Wallscheid, Heidelberg/DE
  Special Lecture
18:00-19:00 Metabolic regulation of blood and bone forming stem cells by the endothelial barrier:
the role of ROS and nitric oxide
  • Tsvee Lapidot, Rehovot/IL
19:30 Welcome Reception and Dinner
Wilseder Hof
09:00-10:30 Session II: Myeloproliferative neoplasia I
Chairs: Tony Green, Cambridge/UK; Carol Stocking, Hamburg/DE
  09:00-09:25
Structural and Molecular Bases of Pathologic Signaling by JAK2 and Tpo Receptor Mutants
in Myeloproliferative Neoplasms: Perspectives for Therapy
  • Stefan Constantinescu, Brussels/BE
  09:25-09:50
Stem cell origin and disease initiation of myeloproliferative neoplasms
  • Radek Skoda, Basel/CH
  09:50-10:15
Genetic basis of Ph- myeloproliferative neoplasms
  • Robert Kralovics, Vienna/AT
  10:15-10:30
The metabolite R-2-hydroxyglutarate (R-2HG), but not S-2HG, collaborates with
HoxA9 to induce monocytic leukemia in vivo
(selected abstract)
  • Anuhar Chaturvedi, Hannover/DE
10:30-11:00 Coffee break
11:00-12:45 Session III: Myeloproliferative neoplasia II
Chairs: Robert Kralovics,  Vienna/AT ; Radek Skoda,  Basel/CH
  11:00-11:25
CALR mutants induce a myeloproliferative disorder through activation of the
thrombopoietin receptor MPL and JAK2
  • William Vainchenker, Villejuif/FR
  11:25-11:50
The myeloproliferative neoplasms, JAK/STAT signalling and stem cell subversion
  • Tony Green, Cambridge/UK
  11:50-12:15
Acute myeloid leukemia: roadblock to differentiation
  • Michael Heuser, Hannover/DE
  12:15-12:30
HSC genetic heterogeneity determines clonal dynamics in PMF (short talk)
  • Ioanna Triviai, Hamburg/DE
  12:30-12:45
Attenuation of PKC Activity Augments Hematopoietic Stem and Progenitor Cells Poll Size and Fitness (short talk)
  • Tata Nageswar Rao, Basel/CH
12:45-14:00 Lunch (Heidemuseum) & Poster viewing
14:00-15:30 Session IV: Canceromics
Chairs: Bertie Goettgens, Cambridge/UK; Phil Koeffler, Los Angeles/US
  14:00-14:25
Acute Leukemia: Genomic Abnormalities, Even Before the Disease Develops
  • Phil Koeffler, Los Angeles/US
  14:25-14:50
Meis transcription factors in normal and leukemic hematopoiesis
  • Keith Humphries, Vancouver/CA
  14:50-15:15
MicroRNA-155 and microRNA-708 are opposing modulators of Hoxa9 activity
in acute myeloid leukemia
  • Florian Kuchenbauer, Ulm/DE
  15:15-15:30
Integrated Analysis of the Human Hematopoietic Non-Coding RNA Landscape Reveals Lnc-RNA
Stem Cell Signature in AML
(selected abstract)
  • Jan-Henning Klusmann, Hannover/DE
15:30-16:00 Coffee break
16:00-17:00 Intermezzo: Immunotherapy I
Chair: Archana Thakur, Charlottesville/US
  16:00-16:25
Off-the-shelf engineered cord blood NK cells for eradication of leukemia
  • Katy Rezvani, Houston/US
  16:25-16:40
Identification of Immune Checkpoint Ligands PVR and PVRL2 as Novel Therapeutic Targets
in Acute Myeloid Leukemia
(selected abstract)
  • Hauke Stamm, Hamburg/DE
17:00-19:00 POSTER SESSION I
19:00 Barbecue and Live Music 'Les amis' - "Emhoff"
09:00-10:30 Session V: Stem cells in homeostasis and disease I
Chairs: Ulrich G. Steidl, New York/US; David Williams, Boston/US
  09:00-09:25
Molecular analysis of individual primitive human hematopoietic cells before and after their stimulation
  • Connie Eaves, Vancouver/CA
  09:25-09:50
Regulatory Network Control of Blood Cell Development
  • Bertie Goettgens, Cambridge/UK
  09:50-10:15
Model-based prediction of long-term molecular response in TKI-treated CML
  • Ingo Roeder, Dresden/DE
  10:15-10:30
Analysis of the subclonal architecture of adult B-ALL reveals highly plastic surface marker
expression contradicting a common stem cell phenotype
(selected abstract)
  • Bartosch Wojcik, Frankfurt a.M./DE
10:30-11:00 Coffee break
11:00-12:30 Session VI: Stem cell in homeostasis and disease II
Chairs: Connie Eaves, Vancouver/CA; Keith Humphries, Vancouver/CA
  11:00-11:25
The role of RhoGTPases in normal and malignant hematopoiesis
  • David Williams, Boston/US
  11:25-11:50
Transcriptional Dysregulation in Precancerous Stem Cells and their Progression to MDS and AML
  • Ulrich G. Steidl, New York/US
  11:50-12:15
Stem cell gene therapy - what cells should we target?
  • Hans-Peter Kiem, Seattle/US
  12:15-12:30
Genetic and functional diversity between single stem cell clones of a patient's ALL sample growing in mice (selected abstract)
  • Irmela Jeremias, Munich/DE
12:30-13:30 Lunch (Heidemuseum) & Poster viewing
13:30-15:30 POSTER SESSION II
15:30-15:45 Vorstellung der Förderprogramme der Deutschen Krebshilfe
  • Matthias Serwe, Bonn/DE
15:45-18:10 Session VII: New targets, novel therapies
Chairs: Olaf Heidenreich, Newcastle upon Tyne/UK; Richard Lock, Sydney/AU
  15:45-16:10
New Agent Testing in Paediatric Leukaemia
  • Richard Lock, Sydney/AU
  16:10-16:25
A novel selective inhibitor of mutant IDH1 promotes differentiation in vivo and prolongs survival in a mouse model of leukemia (selected abstract)
  • Ramya Goparaju, Hannover/DE
  16:25-16:55
Coffee Break
  16:55-17:20
Axl-targeting - a novel treatment approach for AML?
  • Sonja Loges, Hamburg/DE
  17:20-17:45
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes
  • John Pimanda, Sydney/AU
  17:45-18:10
t(8;21) AML is susceptible to G1 CDK inhibition
  • Olaf Heidenreich, Newcastle upon Tyne/UK
19:00 Farewell Dinner - "Emhoff"
09:00-12:00 Session VIII: Immunotherapy I
Chairs: Tuna Mutis, Amsterdam/NL; Paul Veys, London/UK
  09:00-09:25
First-in-man use of gene-edited universal (U)CAR19 T cells to induce remission of
refractory relapsed acute lymphoblastic leukaemia
  • Paul Veys, London/UK
  09:25-09:50
Adoptive T-cell therapy
  • Gerald Willimsky, Berlin/DE
  09:50-10:05
Receptor-transgenic T cells for the Immunotherapy of Multiple Myeloma (short talk)
  • Sara Yousef, Hamburg/DE & Utah/US
10:10-10:40 Coffee break
  10:40-11:05
Immunotherapy of Multiple Myeloma by targeting CD38: antibodies, CART cells and beyond
  • Tuna Mutis, Amsterdam/NL
  11:05-11:30
Enhanced Transfer of Specific Anti-Cancer Immunity by Infusions of Bispecific Antibody Armed T cells Given Prior to Stem Cell Transplant
Archana Thakur, Charlottesville/US
  11:30-11:45
Prognostically favorable B-cell immune responses after allogeneic stem cell transplant define a unique targetable epitope fingerprint of multiple myeloma (selected abstract)
  • Anna Oberle, Hamburg/DE
11:45 Concluding remarks
from 12:00 Departure (packed Lunch)
Search
Newsletter

Yes, keep me updated for this event

@

Dates to remember

  • January 19, 2016
    Start of Abstract Submission
  • February 29, 2016
  • Start of Online Registration
  • March 21, 2016 -Extended-
    End of Abstract Submission
  • April 2016
    Review of Abstracts and Acceptance notification
  • May 31, 2016
  • End of Online Registration
  • June 18 - 21, 2016
  • XXI. Wilsede-Meeting

Main Sponsor

Deutsche Krebshilfe
Deutsche Forschungsgemeinschaft

Meeting Office/Contact

CSI Hamburg

CSi Hamburg GmbH
Conferences | Symposia | Incentives
Jungfrauenthal 22
20149 Hamburg

  +49 40 30770300
  +49 40 30770301
  E-Mail
  Website

Technical support

EventClass GmbH | it - solutions for the event management / it - lösungen für das veranstaltungsmanagement